title: Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy.
abstract: OBJECTIVE
  Comparison of inhaled salmeterol powder vs oral montelukast treatment in patients with persistent asthma who remained symptomatic while receiving inhaled corticosteroids.
  
  
  METHODS
  Randomized, double-blind, double-dummy, parallel-group, multicenter trials of 12-week duration.
  
  
  METHODS
  Outpatients in private and university-affiliated clinics.
  
  
  METHODS
  Male and female patients > or = 15 years of age with a diagnosis of asthma (baseline FEV(1) of 50 to 80% of predicted) and symptomatic despite receiving inhaled corticosteroids.
  
  
  METHODS
  Inhaled salmeterol xinafoate powder, 50 microg bid, or oral montelukast, 10 mg qd.
  
  
  RESULTS
  Treatment with salmeterol powder resulted in significantly greater improvements from baseline compared with montelukast for most efficacy measurements, including morning peak expiratory flow (35.0 L/min vs 21.7 L/min; p < 0.001), percentage of symptom-free days (24% vs 16%; p < 0.001), and the percentage of rescue-free days (27% vs 20%; p = 0.002). Total supplemental albuterol use was decreased significantly more in the salmeterol group compared with the montelukast group (- 1.90 puffs per day vs - 1.66 puffs per day; p = 0.004) and nighttime awakenings per week decreased significantly more with salmeterol than with montelukast (- 1.42 vs - 1.32; p = 0.015). Patients treated with inhaled salmeterol were significantly more satisfied with their treatment regimen and how well, how fast, and how long it worked than were patients who were treated with oral montelukast. The safety profiles for the two treatments were similar.
  
  
  CONCLUSIONS
  In patients with persistent asthma who remain symptomatic while receiving inhaled corticosteroids, adding inhaled salmeterol powder provided significantly greater improvement in lung function and asthma symptoms and was preferred by patients over oral montelukast.
authors.affiliation: Jefferson Medical College, Philadelphia, PA 19107-5083, USA. james.e.fish@mail.tju.edu
authors.forename: J E
authors.initials: JE
authors.lastname: Fish
authors.forename: E
authors.initials: E
authors.lastname: Israel
authors.forename: J J
authors.initials: JJ
authors.lastname: Murray
authors.forename: A
authors.initials: A
authors.lastname: Emmett
authors.forename: R
authors.initials: R
authors.lastname: Boone
authors.forename: S W
authors.initials: SW
authors.lastname: Yancey
authors.forename: K A
authors.initials: KA
authors.lastname: Rickard
mesh_terms: D000085:Acetates / Q000008:administration & dosage*; D000280:Administration, Inhalation; D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage*; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000420:Albuterol / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage*; D001249:Asthma / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000008:administration & dosage*; D003521:Cyclopropanes; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011208:Powders; D011804:Quinolines / Q000008:administration & dosage*; D000068299:Salmeterol Xinafoate; D013440:Sulfides
chemical_list: D000085:Acetates; D000305:Adrenal Cortex Hormones; D000318:Adrenergic beta-Agonists; D018927:Anti-Asthmatic Agents; D001993:Bronchodilator Agents; D003521:Cyclopropanes; D011208:Powders; D011804:Quinolines; D013440:Sulfides; D000068299:Salmeterol Xinafoate; C093875:montelukast; D000420:Albuterol